CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCRWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1439 Interferon-Beta Wiki 1.00
drug259 Aspirin Wiki 0.58
drug2458 Rivaroxaban Wiki 0.45
drug703 Colchicine Wiki 0.32

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19

Evaluation of the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection using an IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard (FDA validated commercial serologic test).

NCT04510454 Cancer COVID Diagnostic Test: Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR

Primary Outcomes

Description: Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard (FDA validated commercial serologic test)

Measure: To determine the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection

Time: At inclusion

Secondary Outcomes

Description: Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard

Measure: To determine the RT-qPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection

Time: Third week after inclusion

Description: Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard

Measure: To determine the ddPCR and RT-qPCR abilities to detect the SARS-CoV-2 in oropharyngeal samples of symptomatic patients with suspected COVID-19 infection

Time: Third week after inclusion

Description: Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard

Measure: To determine the ability of a clinical diagnosis based both on patients' symptoms and chest CT-scan to detect the SARS-CoV-2 in symptomatic patients with suspected COVID-19 infection

Time: Third week after inclusion

Description: Using ddPCR and RT-qPCR assays

Measure: To determine the agreements between nasopharyngeal samples and oropharyngeal samples

Time: At inclusion

Description: Using ddPCR and RT-qPCR assays

Measure: To determine the agreements between a clinical diagnosis and ddPCR and RT-qPCR assays

Time: At inclusion

Description: Rate calculated from the date of the first diagnostic procedure to the date of death of any cause

Measure: To assess the 28-day mortality rate

Time: Up to the follow-up end (28 days after inclusion)

Description: Demographics, type of tumor, type of anticancer, treatment, comorbidities, biological parameters

Measure: To determine potential predictive factors of death among patients' characteristics

Time: Up to the follow-up end (28 days after inclusion)

Description: After adjusting on main clinical characteristics and treatment type

Measure: To evaluate the over risk of death of patients COVID+ versus COVID-

Time: Up to the follow-up end (28 days after inclusion)

Other Outcomes

Description: Comparison of our "in-house" test to the commercial serology test from EUROIMMUN used for the study

Measure: To evaluate the sensibility, specificity and diagnostic accuracy of "in-house" serologic test for the SARS-CoV-2 detection

Time: At inclusion

No related HPO nodes (Using clinical trials)